PTCB Medications: What to Study for the PTCE

Domain 1 is classification work, not a hidden official list

Medications is 35% of the current PTCE outline. That is the largest domain. Put medication-identification items into practice in Passy → after you can name the knowledge areas, not after you download an unofficial “PTCB Top 200” spreadsheet.

PTCB’s statements cover:

• Generic names, brand names, and classifications
• Therapeutic duplications
• Drug interactions and contraindications (some calculation-based)
• Strengths, doses, dosage forms, routes, handling, and duration of drug therapy (some calculation-based)
• Common and severe side effects, adverse effects, and allergies
• Indications and uses
• Drug stability (some calculation-based)
• Proper storage

This is exam-prep knowledge for technician recognition and pharmacist alert. It is not a license to choose therapy for a real patient.

Study by class, then attach a few high-use examples

Suffix patterns help classification, which the outline actually names:

• ACE inhibitors often end in -pril (lisinopril, enalapril)
• Beta blockers often end in -olol
• HMG-CoA reductase inhibitors often end in -statin

Those patterns are study tools. They are not a claim that every drug in a class behaves identically, and they are not an official PTCB mnemonic sheet.

Therapeutic duplication is a technician catch: two ACE inhibitors on the profile is a pharmacist question, not a “fill both because the directions differ.”

Do you need the Top 200 drugs? is the list-myth page. Use it when search results promise an official roster. Stay here for the domain map.

Interactions and contraindications are flags, not dosing projects

A warfarin-plus-regular-NSAID request is a bleeding-risk flag for the pharmacist. An ACE inhibitor plus potassium-sparing overlap is a monitoring flag. The outline wants you to recognize those patterns and involve the pharmacist. It does not ask you to redesign the regimen.

Storage and stability are Domain 1 as well: refrigerator versus room temperature, light-sensitive products, beyond-use thinking where the outline marks calculation-based stability. That is product handling, not compounding from scratch. Compounding as a dedicated PTCE area was removed in 2026. PTCB exam changes in 2026 is the delta.

How this domain touches the others

Look-alike names and high-alert drugs also appear in Patient Safety. Controlled-substance scheduling is Federal Requirements, even when the product is a medication you also studied for class. Federal Requirements and Patient Safety take those layers.

Mix Domain 1 with the other three PTCE domains in Passy → so brand/generic drill does not eat the week.

PTCB / PTCE study guide is how to weight 35% against the rest.

Keep brand-class medication questions in the Passy rotation → after each class block.

The useful next step is recognition under a clock, not a longer unofficial list.

Shape the next PTCE session in Passy → around classes that still collapse into look-alike pairs.